Literatur
-
1
Algenstaedt P, Hamann A.
Glitazone - eine neue Substanzklasse in der Behandlung des Typ 2-Diabetes.
Dtsch Med Wochenschr.
2001;
126
951-952
-
2
Al-Salman J, Arjomand H, Kemp D. et al .
Hepatocellular injury in a patient receiving rosiglitazone: a case report.
Ann Int Med.
2000;
132
121-124
-
3
Aronoff S, Rosenblatt S, Braithwaite S. et al .
Pioglitazone Hydrochloride Monotherapy Improves Glycemic Control In The Treatment of Patients With Type 2 Diabetes.
Diabetes Care.
2000;
23
1605-1611
-
4
Arzneimittelkommission der deutschen Ärzteschaft .
Schwerwiegende Leberreaktion unter Rosiglitazon.
Dt Ärzteblatt.
2001;
A98
1987
-
5
Bell D.
Ethics in Diabetic Clinical Trials.
Diabetes Care.
2001;
24
606
-
6
Day C.
Thiazolidinediones: a new class of antidiabetic drugs.
Diabet Med.
1999;
16
179-192
-
7
Forman L, Simmons D, Diamond R.
Hepatic failure in a patient taking rosiglitazone.
Ann Int Med.
2000;
132
118-121
-
8
Gale E.
Lessons from the glitazones: a story of drug development.
Lancet.
2001;
357
1870-1875
-
9
Gottlieb S.
Company played down drug`s risks, report says.
Br Med J.
2001;
322
696
-
10
Hachey D, O`Neil M, Force R.
Isolated elevation of alkaline phosphatase level associated with rosiglitazone.
Ann Int Med.
2000;
133
752
-
11 Los Angeles Times 11. März 2001: Paper: Co. Knew of Drug-Liver Link. www.mindfully.org/Industry/Warner-Lambert-Liver-Damage.htm
-
12 National Institute for Clinical Excellence .Guidance on Rosiglitazone for Type 2 Diabetes Mellitus. Technology Appraisal Guidance -. No.9 August 2000 www.nice.org.uk
-
13
Ravinuthala R, Nori U.
Rosiglitazone Toxicity. Letter to the editor.
Ann Int Med.
2000;
133
658
-
14
Richter B.
Einsatz der Glitazone beim Typ-2-Diabetes: eine kritische Stellungnahme.
Dtsch Med Wochenschr.
2001;
126
606
-
15
The Diabetes Prevention Program Research Group .
The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.
Diabetes Care.
1999;
22
623-634
-
16
Tolman K.
Thiazolidinedione hepatotoxicity: a class effect?.
Int J Clin Pract.
2000;
113
29-34
(Suppl))
-
17
UK Prospective Diabetes Study (UKPDS) Group .
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).
Lancet.
1998;
352
854-865
-
18
UK Prospective Diabetes Study (UKPDS) Group .
Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
Lancet.
1998;
352
837-853
-
19
Watkins P, Whitcomb R.
Hepatic Dysfunction Associated with troglitazone.
New Engl J Med.
1998;
338
916-917
-
20 Wolfe M. Statement. Director, Public Citizen`s Health Research Group FDA Endocrine and Metabolic Drugs Advisory Committee Meeting in Troglitazone March 26, 1999 www.citizen.org/ hrg/ PUBLICAIONS/1476.htm
Dr. med. Helmut Kleinwechter
Diabetes-Schwerpunktpraxis
Alter Markt 11
24103 Kiel
Phone: 0431/95807
Fax: 0431/95805
Email: praxis.kleinwechter.demandt@t-online.de
